ArticleJournal of thoracic disease2024
Nomogram model for predicting long-term survival in esophageal cancer patients with metastasis after treatment: a SEER-based study.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of a clinically interpretable risk scoring system for predicting one-year all-cause mortality in esophageal cancer: a population-based study.Journal of thoracic disease · 2026Article
- Colorectal cancer sidedness: prognostic implications and the predictive role of artificial intelligence.BMC medical informatics and decision making · 2026Article
- Interpretable machine learning models to predict survival in esophageal cancer: a study based on the SEER database and external validation in China.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a large variance in the long-term survival of esophageal cancer (EC) patients with metastasis after treatment. This study was designed to analyze long-term survival of metastatic EC patients after surgery, radiotherapy and chemotherapy. Methods: A retrospective cohort of EC patients with metastasis received surgery, radiotherapy and chemotherapy from 2004 to 2015 was obtained from the Surveillance, Epidemiology and End Results (SEER) database. Univariate Cox and complete subset regression analyses were performed to select prognostic factors. Nomograms were established to predict 3-, 5-, and 8-year overall survival (OS), and their performance was evaluated by receiver operating characteristic (ROC) curve and calibration curve. Results: Age at diagnosis [hazard ratio (HR): 1.01; 95% confidence interval (CI): 1.00, 1.02; P=0.04], EC of other sites (HR: 1.78; 95% CI: 1.29, 2.45; P<0.001), lymph node involvement (HR: 1.37; 95% CI: 1.08, 1.37; P=0.009), and poorly differentiated or undifferentiated (grade III or IV) (HR: 1.39; 95% CI: 1.20, 1.76; P=0.006) was the independent risk factors for poor OS in EC patients. Female (HR: 0.58; 95% CI: 0.38, 0.88; P=0.01) showed reduced risks of showing poor OS compared with male population. The established nomograms based on these predictors showed satisfactory discrimination efficacy for predicting 3-, 5-, and 8-year OS in metastatic EC patients after treatment. Conclusions: The nomograms showed good efficacy in predicting 3-, 5-, and 8-year OS among metastatic EC patients after surgery, radiotherapy and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.